Due to HAART and consequent decline in mortality from infectious complications, HIV patients have an increasing burden of non-AIDS defining cancers. Data on their safety and efficacy is unknown as these patients were excluded from clinical trials due to concern of unforeseen side effects. Objectives. The main objective of our study was to evaluate the efficacy and safety profile of PD-1 and PD-L1 inhibitors in HIV patients being treated for advanced cancers and to assess the impact of these drugs on HIV status of the patients specifically CD4 count and HIV viral load. Materials and Methods. This was a retrospective analysis of data of 17 patients HIV treated with one of the PD-1/PD-L1 inhibitors (Nivolumab, Pembrolizumab, Atezolizumab, Durvalumab, or Avelumab) for advanced cancer. Results. 10 out of 17 patients responded to therapy. 7 patients, all of whom had shown response to therapy, were alive and 4 were still on checkpoint inhibitor. 10 patients including all 7 nonresponders had died. Responders had minimum of 15 weeks of response while one had ongoing continued response at 34 weeks. Side effects were seen in 7 patients and only one patient needed cessation of therapy. CD4 counts were stable on treatment while HIV RNA remained undetectable. Conclusion. PD-1 and PD-L1 inhibitors appear to have comparable efficacy and tolerable side effect profile and have no effect on HIV markers when used in HIV patients with advanced cancers.

1. Introduction

HIV patients have a 30% to 40% lifetime risk of malignancy, making cancer a major cause of morbidity and mortality in this population [1]. Advances in highly active antiretroviral therapy (HAART) have made the life expectancy of HIV patients similar to the general population [2], causing a marked growth in the burden of HIV patients with cancer. Despite a dramatic decline in acquired immune deficiency syndrome (AIDS) defining cancers, AIDS patients continue to have elevated rates of lung, prostate, anal, and hepatocellular carcinoma and Hodgkin’s lymphoma [3].

Checkpoint inhibitors are revolutionizing cancer therapy. Checkpoint inhibitors that have been approved by the Food and Drug Administration (FDA) include cytotoxic T lymphocyte associated protein 4 (CTLA-4) blocker Ipilimumab, PD-1 blockers Nivolumab and Pembrolizumab and PD-L1 blockers Atezolizumab, Avelumab and Durvalumab. They are currently approved for nonsmall cell lung cancer (NSCLC), melanoma, bladder cancer, non-Hodgkin’s lymphoma, renal cell cancer, and hepatocellular cancer among the most common and are expected to be approved for more in the future. In HIV patients, studies have shown an increased expression of PD-1 on HIV-positive CD8 cells.
and its level correlated directly with disease progression and viremia [4]. As immune checkpoints play an important role in host response to chronic infections like HIV, trials involving these drugs have typically excluded HIV patients due to concern for unforeseen side effects. Further, the effect of immune checkpoint inhibitors on HIV suppression is unknown. Here we present our experience with the use of PD-1 and PD-L1 inhibitors in HIV patients with advanced cancers.

2. Materials and Methods

This is a retrospective evaluation of HIV patients treated with a PD-1 or PD-L1 inhibitor at Grady Memorial Hospital, Atlanta, GA, and Duke University Hospital, Durham, NC. Institutional approval was obtained at both sites. We evaluated HIV patients treated with one of the PD-1 or PD-L1 inhibitors (Nivolumab, Pembrolizumab, Atezolizumab, Durvalumab, or Avelumab) for any cancer. We collected patient demographics, type and stage of cancer, drug given, response, and side effects. We also looked at type of ARV therapy, HIV viral load, and CD4 count trends. We used the response evaluation criteria in solid tumors (RECIST) to evaluate radiologic response to therapy. Patients were categorized as responders to therapy if they achieved complete response, partial response, or stable disease as per the RECIST criteria [5]. Safety was assessed by evaluating the incidence of clinical adverse events and laboratory abnormalities which were graded according to National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE v.4.0). Patients were asked at each visit for occurrence of adverse events known to be associated with use of PD-1/PDL-1 inhibitors. Thyroid and cortisol levels were included with routine labs at each visit. At our infectious disease clinic, HIV viral load, and CD4 counts are checked every 4 to 6 weeks as part of follow up of HIV patients.

3. Results

A total of 17 HIV-positive cancer patients were treated with either a PD-1 or PD-L1 inhibitor. There were 3 females and 14 male patients with a median age of 54 years at cancer diagnosis. Lung cancer was the most common cancer seen in 10 patients. Two patients had hepatocellular cancer, 2 anal cancers, 1 kidney cancer, 1 Non-Hodgkin's lymphoma, and 1 advanced basal cell carcinoma. Thirteen patients had stage 4 disease (Table 1).

All patients were receiving HAART with HIV related data available for 16 of the 17 patients. Emtricitabine/Tenofovir and Dolutegravir were the most commonly used HAART combination used in 7 patients. The median CD4 count at initiation of therapy was 425 cells/µl (range 150-795 cells/µl). Low level HIV viremia was detected in 2 patients, while in the other 14 patients, HIV RNA level was below detection threshold (Table 2).

Nivolumab was the most commonly used drug (n=13) followed by Pembrolizumab (n=3) and Atezolizumab (n=1). PD-L1 expression was tested in 5 patients, of which 3 had expression of less than 1%. One patient had PD-L1 expression of 20% and another of 90%; both received Pembrolizumab.

4. Outcome

The patients received a median of 10 doses of the drug. Ten patients responded to treatment, of whom 5 had partial response (PR) and 5 had stable disease (SD) (Table 1). In the lung cancer group, (the largest group with 10 patients), 3 patients achieved PR and 3 had SD leading to an overall response rate (ORR) of 60%. Two patients died before response could be assessed and two had progressive disease on therapy. Both patients with hepatocellular cancer responded, one had PR and the other SD. One patient with renal cell carcinoma and one with invasive basal cell also responded to therapy. Seven patients did not respond to therapy, of whom 4 died before response could be assessed. There were 2 anal carcinoma patients, and neither showed response to therapy. At the time of data analysis, 7 patients were alive (all patients alive had responded to therapy), and 4 are continuing their treatment drug. Of the 4 patients who continue to be on treatment with continued response, 2 have lung cancer, one has hepatocellular cancer, and one has invasive basal cell carcinoma. Ten patients died, including all 7 nonresponders. Eight patients died due to progression of cancer and 2 from sepsis. One of the patients who died from sepsis (patient 2) died within a few days of getting his first dose of Nivolumab and his cause of death was not attributed to the drug. Patient 15 had stable disease but stopped Nivolumab after 11 doses due to disease progression and was placed on a tyrosine kinase inhibitor (TKI). He had stopped HAART (reason unknown), leading to a drop in CD4 count and rise in HIV viral load. He died about 18 weeks after last dose of Nivolumab.

5. HIV Markers and Adverse Events

At 12 weeks median CD4 count was 402 cells/µl (range 120-597 cells/µl) while HIV RNA remained below detection threshold in 11 patients whose data was available. One of the patients with low level HIV viremia at the initiation of therapy had complete suppression of HIV RNA with rise in CD4 from 163 to 285 cells/µl. One patient showed a fall in CD4 count from 150 to 120 cells/µl, but his viral load remained undetectable and he remains on treatment with a continued partial response.

Four patients had concomitant hepatitis C and 1 had chronic hepatitis B; none experienced reactivation. Nausea/vomiting (4 patients), thyroid abnormalities (3 hypothyroidism and 2 with decreased TSH), and fatigue (2 patients) were the most common side effects (Table 1). One patient (patient 3), who had NSCLC developed pneumonitis after receiving 10th dose, managed with high dose steroids and his Nivolumab was stopped permanently. One patient developed grade 2 colitis after the 6th dose which recovered with holding therapy and did not recur with restarting the drug. Both these patients were alive at the time of analysis. The 3 patients
### Table 1: Clinical characteristics, response, and toxicity profile of patients.

| Patient | Age/sex | Cancer and stage | PD-L1 expression. Other mutation | Previous lines of therapy | Best response | Length of therapy | Toxicity (grade) | Alive or dead |
|---------|---------|------------------|-----------------------------------|---------------------------|---------------|------------------|-----------------|---------------|
| 1       | 57/F    | Lung SCC IV      | <1%                               | Carbo Tax 2 AT - 3 doses  | NA            | NA               | D (PD)          |               |
| 2       | 40/M    | Lung ADC IV      | NA                                | Carbo Tax 3 then Nivo 1   | NA            | NA               | D(sepsis)       |               |
| 3       | 62/M    | Lung SCC II      | NA                                | Lobectomy then Cis Docetaxel 1 then Carbo Tax 1 then Nivo 10 | SD            | 28 weeks. stopped due to pneumonitis | Pneumonitis (3) | Alive         |
| 4       | 45/M    | Lung ADC IV      | NA                                | Carbo Alimta 4 then Alimta 4 then Nivo 10 | PR            | 24 and ongoing | Colitis (2) Rash (1) | Alive         |
| 5       | 45/F    | Lung ADC IV      | <1%                               | Carbo Alimta 4 then Alimta 13 then Nivo 17 then Docetaxel | PR            | 34 weeks        | Alive           |               |
| 6       | 56/M    | Lung SCC IV      | NA                                | Pembro 6 then Carbo Tax 2  | SD            | 16 weeks        | D(PD)           |               |
| 7       | 55/M    | Lung ADC IV      | 20% HER 2 Neu                     | Carbo Alimta 4 then Alimta 3 then Pembro 7 then Trastu + Pertuzumab | SD            | 22 weeks        | Fatigue (1) Hypothyroidism | alive         |
| 8       | 60/M    | Lung ADC IV      | NA                                | Carbo Alimta 4 then Alimta 10 then Nivo 8 | PR            | 16 and ongoing | Elevated TSH | alive         |
| 9       | 58/M    | Lung mixed IV    | NA                                | Cis Etopo x5 then Nivo 5   | PD            | NA               | D(PD)           |               |
| 10      | 48/M    | Lung ADC IV      | 90% EGFR                          | Erlotinib 5 months then Pembro 2 | PD            | NA               | D(PD)           |               |
| 11      | 40/F    | Anal SCC IV      | NA                                | Chemo RT hen CarboTax 5 then Nivo 1 | NA            | NA               | D (PD)          |               |
| 12      | 54/M    | Anal SCC IV      | NA                                | Mitomycin Xeloda then Nivo 13 | PD            | 26 weeks        | Hypothyroidism | D(PD)         |
| 13      | 43/M    | HCC III          | NA                                | Regorafinib 24 then Nivo 12 | SD            | 25 weeks        | Fatigue (1) | D(PD)         |
| 14      | 44/M    | HCC IV           | NA                                | RFA, TACE hen Soafenib 3 months then Nivo 12 | PR            | 25 and ongoing | Hyperglycemia, Hypothyroidism | Alive         |
| 15      | 59/M    | RCC III          | NA                                | Sorafenib then Sunitinib then Everolimus the Nivo 11 then Axitinib | SD            | 22 weeks        | Elevated TSH | D(sepsis)     |
| 16      | 42/M    | DLBCL IV         | NA                                | RCHOP then RICE PBCT then Nivo 10 then Rev Rtx 1 | PD            | 22 weeks        | D(PD)           |               |
| 17      | 56/M    | Invasive basal   | NA                                | Vsmodegib 6 then Nivo 10   | PR            | 24 weeks and ongoing | Elevated TSH | alive         |

Abbreviations: SCC: squamous cell cancer. ADC: adenocarcinoma. RCC: renal cell cancer. HCC: hepatocellular cancer. DLBCL: diffuse large B cell lymphoma. Nivo: Nivolumab. Pembro: Pembrolizumab. AT: Atezolizumab. NA: not available. SD: stable disease. PR: partial response. PD: progressive disease. Carbo Tax: Carboplatin and Paclitaxel. Cis: Cisplatin. Trastu: Trastuzumab. Cis Etopo: Cisplatin Etoposide. RT: Radiation therapy. RFA: radiofrequency ablation. RCHOP: Rituximab, Cyclophosphamide, Adriamycin, Oncovin, Prednisone. RICE: Rituximab, Ifosfamide, Carboplatin, Etoposide. SCT: stem cell transplant. RR: Rituximab, Revlimid. D: Dead.

With hypothyroidism were given thyroid replacement while the 2 patients with low TSH had normal free T4 and were monitored periodically. All immune related adverse events were seen between the 3rd and 5th doses of the treatment; the colitis developed after the 6th dose while pneumonitis developed after the 10th dose of the drug.
Table 2: HIV-related markers while on immune checkpoint inhibitor therapy.

| Patient | HAART regimen | CD4 (cells/μl) at baseline | CD4 (cells/μl) at 12 weeks | VL (copies/ml) at baseline | VL (copies/ml) at 12 weeks |
|---------|----------------|----------------------------|----------------------------|----------------------------|----------------------------|
| 1       | FTC/TDF + DTG  | 573                        | NA*                        | 0                          | NA*                        |
| 2       | EVG/c/FTC/TDF  | 242                        | NA*                        | <400                       | NA*                        |
| 3       | DTG, DRV/r     | 795                        | 552                        | <400                       | 0                          |
| 4       | ABC/DTG/3TC    | 424                        | 460                        | 0                          | 0                          |
| 5       | FTC/TDF + DTG  | 427                        | 402                        | 0                          | <400                       |
| 6       | FTC/TDF + DRV  | 626                        | 517                        | 0                          | 0                          |
| 7       | ETR, DTG, DRV/r| 607                        | 597                        | <20                        | <20                        |
| 8       | EFV/FTC/TDF    | 305                        | NA*                        | <20                        | NA*                        |
| 9       | FTC/TAF + DTG  | NA                         | NA*                        | NA                         | NA*                        |
| 10      | RPV/FTC/TDF    | 469                        | NA*                        | <20                        | NA*                        |
| 11      | FTC/TDF + DTG  | 624                        | NA*                        | 500                        | NA*                        |
| 12      | ABC/3TC/DTG    | 250                        | 262                        | <20                        | <20                        |
| 13      | FTC/TDF + DTG  | 326                        | 431                        | 0                          | 0                          |
| 14      | FTC/TDF + DTG  | 150                        | 120                        | <20                        | <20                        |
| 15      | TDF/RAL        | 461                        | 376                        | <400                       | <400                       |
| 16      | DRV/c + DTG    | 163                        | 285                        | 89                         | <20                        |
| 17      | FTC/TDF + DTG  | 364                        | 370                        | 0                          | <400                       |

Abbreviations: NA: data not available. *: died before response could be assessed. VL: viral load.

HAART regimen: FTC/TDF: emtricitabine/tenofovir disoproxil fumarate. DTG: dolutegravir. EVG/c: elvitegravir/cobicistat. DRV/r: darunavir/ritonavir. ABC: abacavir. 3TC: lamivudine. TDF: tenofovir disoproxil fumarate. RAL: raltegravir. DRV/c: darunavir. ETR: etravirine. EFV: efavirenz. TAF: tenofovir alafenamide. RPV: rilpivirine.

6. Discussion

The success of HAART has brought a dramatic improvement in HIV control with a steep decline in mortality from opportunistic infections and AIDS defining cancers, with corresponding increased prevalence of non-AIDS defining cancers and their emergence as a cause of mortality [6]. The rates of lung and prostate cancer are expected to continue increasing in the coming decades [3]. As a result, it is imperative that promising therapeutic options like checkpoint inhibitors remain available to this population of cancer patients.

Checkpoint inhibitors have induced significant responses in NSCLC [7], melanoma [8], Hodgkin’s lymphoma [9], kidney [10], and bladder cancer [11]. However, due to the role of PD-1/PD-L1 pathway in chronic HIV infection and fear of unforeseen adverse events, HIV patients were excluded from these trials.

Several case reports have been published showing the efficacy of PD-1 inhibitors in HIV patients in lung cancer [12–14], Hodgkin’s lymphoma [15], melanoma [16, 17], and anal cancer [18]. In these reports and another large series involving 7 NSCLC patients [19], checkpoint inhibitors were tolerated well. Our series is the largest study so far, comprising 17 patients and encompassing a variety of cancers. The duration of response in our study ranged from 15 weeks to 34 weeks ongoing which is similar to that reported in clinical trials involving non-HIV patients. In our lung cancer patients, we saw response in 60% of patients. Our series is small and retrospective, and we cannot draw definitive conclusions, but we see excellent tolerability of PD-1/PD-L1 inhibitors in HIV patients. Only 1 patient needed to discontinue the drug due to pneumonitis. Nine patients experienced immune related side effects which were grade 1 or 2 and were easily managed. None of the patients had reactivation of HIV and all had stable CD4 counts. We did not see any activation or flare of autoimmune disorders. Our series aims to add to the accumulating knowledge and experience regarding the efficacy of checkpoint inhibitors in HIV patients with cancer. One advantage of our study is the demonstration of benefit across a variety of cancers. In conclusion, our series, though small, shows that anti-PD1 therapy appears to be safe and effective in HIV patients with cancer. However, larger studies are needed to address questions about their efficacy and adverse effect profile in this patient population. Many clinical trials with Nivolumab in HIV patients with NSCLC (NCT03304093) and Pembrolizumab in relapsed refractory or disseminated neoplasms (NCT02595866) are underway.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.
Authors’ Contributions

Shahla Bari was responsible for conceptualizing the idea, data acquisition, extraction, literature review, manuscript preparation, and editing. Jameel Muzaffar, MD, was responsible for manuscript guidance and preparation. Austin Chan was responsible for mentoring and guiding the study and helped in increasing the size of the study. Sanjay Jain helped in conceptualizing the idea and proofreading the manuscript. Ahmad M. Haider was responsible for statistical analysis and chart preparation. Marjorie Adams Curry was responsible for providing partial list of patients who were treated with PD-L1 inhibitors. Christopher Hostler significantly helped in data acquisition, extraction, and guidance in manuscript preparation.

Acknowledgments

The results of this abstract were presented as an article at the Infectious Disease Society of America, ID week, October, 2018 at San Francisco CA.

References

[1] J.-P. Spano, D. Atlan, J.-L. Breau, and D. Farge, “AIDS and non-AIDS-related malignancies: A new vexing challenge in HIV-positive patients - Part I: Kaposi’s sarcoma, non-Hodgkin’s lymphoma, and Hodgkin’s lymphoma,” *European Journal of Internal Medicine*, vol. 13, no. 3, pp. 170–179, 2002.

[2] H. Samji, A. Cescon, R. S. Hogg et al., “Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada,” *PLoS ONE*, vol. 8, no. 12, Article ID e81355, 2013.

[3] M. S. Shieles, J. Y. Islam, P. S. Rosenberg, H. I. Hall, E. Jacobson, and E. A. Engels, “Projected Cancer Incidence Rates and Burden of Incident Cancer Cases in HIV-Infected Adults in the United States Through 2030,” *Annals of Internal Medicine*, vol. 168, no. 12, p. 866, 2018.

[4] J.-Y. Zhang, Z. Zhang, X. Wang et al., “PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors,” *Blood*, vol. 109, no. 11, pp. 4671–4678, 2007.

[5] E. A. Eisenhauer, P. Therasse, J. Bogaerts et al., “New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1),” *European Journal of Cancer*, vol. 45, no. 2, pp. 228–247, 2009.

[6] H. A. Robbins, R. M. Pfeiffer, M. S. Shieles, J. Li, H. I. Hall, and E. A. Engels, “Excess cancers among HIV-infected people in the United States,” *Journal of the National Cancer Institute*, vol. 107, no. 4, 2015.

[7] H. Borghaei, L. Paz-Ares, L. Horn et al., “Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer,” *The New England Journal of Medicine*, vol. 373, no. 17, pp. 1627–1639, 2015.

[8] J. D. Wolchok, H. Kluger, M. K. Callahan et al., “Nivolumab plus ipilimumab in advanced melanoma,” *The New England Journal of Medicine*, vol. 369, no. 11, pp. 122–133, 2013 (Arabic).

[9] A. Younes, A. Santoro, M. Shipp et al., “Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial,” *The Lancet Oncology*, vol. 17, no. 9, pp. 1283–1294, 2016.

[10] R. J. Motzer, B. Escudier, and D. F. McDermott, “Nivolumab versus everolimus in advanced renal-cell carcinoma,” *The New England Journal of Medicine*, vol. 373, no. 19, pp. 1803–1813, 2015.

[11] P. Sharma, M. Retz, A. Siefer-Radtke et al., “Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial,” *The Lancet Oncology*, vol. 18, no. 3, pp. 312–322, 2017.

[12] B. McCullar, T. Alloway, and M. Martin, “Durable complete response to nivolumab in a patient with HIV and metastatic non-small cell lung cancer,” *Journal of Thoracic Disease*, vol. 9, no. 6, pp. E540–E542, 2017.

[13] M. Henrich, K. Schipek-Voigt, H. Jaeger et al., “Nivolumab in HIV-related non-small-cell lung cancer,” *Annals of Oncology*, vol. 28, no. 11, p. 2890, 2017.

[14] A. Guihot, A.-G. Marcelin, M.-A. Massiani et al., “Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer,” *Annals of Oncology*, vol. 29, no. 2, pp. 517–518, 2018.

[15] J. D. Sandoval-Sus, F. Mogollon-Duffo, A. Patel et al., “Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy,” *Journal for ImmunoTherapy of Cancer*, vol. 5, no. 1, 2017.

[16] D. Davar, M. Wilson, C. Pruckner, and J. M. Kirkwood, “PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV,” *Case Reports in Oncological Medicine*, vol. 2015, Article ID 737389, 5 pages, 2015.

[17] M. V. Hepp, M. Schlaak, T. K. Eigentler et al., “Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients,” *Annals of Oncology*, vol. 28, no. 12, pp. 3014–3016, 2017.

[18] V. K. Morris, M. E. Salem, and H. Nimeiri, “Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study,” *The Lancet Oncology*, vol. 18, no. 4, pp. 446–453, 2017.

[19] L. Ostios-Garcia, J. Faig, G. C. Leonardi et al., “Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer,” *Journal of Thoracic Oncology*, vol. 13, no. 7, pp. 1037–1042, 2018.